A VHL-based PROTAC EZH2 degrader was subsequently tested in lymphomas; it was demonstrated to be more efficient than CRBN ligand-based degraders in degrading EZH2, showed advantages over common inhibitors in inhibiting tumor growth in lymphoma xenografts in vivo, and had no obvious toxicity. This evidence concerns the gene VHL and neoplasm.